Duyuru • Apr 02
China Pharma Holdings, Inc. announced delayed annual 10-K filing On 04/01/2026, China Pharma Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (161% increase in shares outstanding). Market cap is less than US$10m (US$4.57m market cap). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (US$4.1m revenue). Reported Earnings • Nov 14
Third quarter 2025 earnings released: US$0.17 loss per share (vs US$0.65 loss in 3Q 2024) Third quarter 2025 results: US$0.17 loss per share (improved from US$0.65 loss in 3Q 2024). Revenue: US$756.2k (down 31% from 3Q 2024). Net loss: US$651.5k (loss narrowed 42% from 3Q 2024). Duyuru • Nov 05
China Pharma Holdings, Inc., Annual General Meeting, Dec 30, 2025 China Pharma Holdings, Inc., Annual General Meeting, Dec 30, 2025, at 08:01 China Standard Time. Location: conference room, 2nd floor, jiahai building, no. 17 jinpan road, haikou, hainan province china 570216 China Reported Earnings • Aug 15
Second quarter 2025 earnings released: US$0.16 loss per share (vs US$0.89 loss in 2Q 2024) Second quarter 2025 results: US$0.16 loss per share (improved from US$0.89 loss in 2Q 2024). Revenue: US$1.03m (up 11% from 2Q 2024). Net loss: US$528.4k (loss narrowed 63% from 2Q 2024). Reported Earnings • May 15
First quarter 2025 earnings released: US$0.24 loss per share (vs US$0.73 loss in 1Q 2024) First quarter 2025 results: US$0.24 loss per share (improved from US$0.73 loss in 1Q 2024). Revenue: US$1.14m (down 17% from 1Q 2024). Net loss: US$785.6k (loss narrowed 18% from 1Q 2024). New Risk • Apr 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 120% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$758k free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Market cap is less than US$10m (US$7.24m market cap). Minor Risk Revenue is less than US$5m (US$4.5m revenue). New Risk • Apr 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$758k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$758k free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (US$5.07m market cap). Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Revenue is less than US$5m (US$4.5m revenue). Reported Earnings • Apr 01
Full year 2024 earnings released: US$0.27 loss per share (vs US$0.91 loss in FY 2023) Full year 2024 results: US$0.27 loss per share. Revenue: US$4.53m (down 35% from FY 2023). Net loss: US$4.74m (loss widened 54% from FY 2023). New Risk • Feb 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (US$4.00m market cap). Duyuru • Dec 13
China Pharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.6 million. China Pharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.6 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: Registered Direct Offering New Risk • Nov 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$751k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$751k free cash flow). Shareholders have been substantially diluted in the past year (182% increase in shares outstanding). Market cap is less than US$10m (US$3.64m market cap). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Duyuru • Nov 05
China Pharma Holdings, Inc., Annual General Meeting, Dec 23, 2024 China Pharma Holdings, Inc., Annual General Meeting, Dec 23, 2024, at 09:00 China Standard Time. Location: conference room, 2nd floor, jiahai building, no. 17 jinpan road, hainan province, haikou China New Risk • Sep 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Market cap is less than US$10m (US$4.04m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Reported Earnings • Aug 16
Second quarter 2024 earnings released: US$0.089 loss per share (vs US$0.30 loss in 2Q 2023) Second quarter 2024 results: US$0.089 loss per share. Revenue: US$924.9k (down 16% from 2Q 2023). Net loss: US$1.44m (loss widened 143% from 2Q 2023). Reported Earnings • May 17
First quarter 2024 earnings released: US$0.073 loss per share (vs US$0.29 loss in 1Q 2023) First quarter 2024 results: US$0.073 loss per share. Revenue: US$1.37m (down 30% from 1Q 2023). Net loss: US$955.9k (loss widened 101% from 1Q 2023). Reported Earnings • Apr 02
Full year 2023 earnings released: US$0.91 loss per share (vs US$3.78 loss in FY 2022) Full year 2023 results: US$0.91 loss per share (improved from US$3.78 loss in FY 2022). Revenue: US$7.01m (down 14% from FY 2022). Net loss: US$3.08m (loss narrowed 23% from FY 2022). New Risk • Feb 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Market cap is less than US$10m (US$4.61m market cap). Duyuru • Nov 29
China Pharma Holdings, Inc. Announces the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device China Pharma Holdings, Inc. announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China. According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases. This device has a utility model patent; Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old; In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device. Reported Earnings • Nov 16
Third quarter 2023 earnings released: US$0.059 loss per share (vs US$0.16 loss in 3Q 2022) Third quarter 2023 results: US$0.059 loss per share (improved from US$0.16 loss in 3Q 2022). Revenue: US$1.80m (down 8.3% from 3Q 2022). Net loss: US$777.6k (loss narrowed 1.7% from 3Q 2022). Duyuru • Nov 08
China Pharma Holdings, Inc., Annual General Meeting, Dec 17, 2023 China Pharma Holdings, Inc., Annual General Meeting, Dec 17, 2023, at 20:00 US Eastern Standard Time. Location: Conference Room, 2nd Floor, Jiahai Building, No No. 17 Jinpan Road, Haikou, Hainan Province, China 570216 China China Agenda: To elect three independent director nominees to company Board of Directors to serve until the next annual meeting and until their successors are elected and qualified; to approve the Amendment No.1 to the company’s Amended and Restated 2010 Long-Term Incentive Plan; to consider and approve an amendment to the Articles of Incorporation of the company to effect a reverse stock split during the course of the following year, at a ratio of up to 1:10, such that every holder of common stock, par value $0.001 per share, of the company shall receive one share of Common Stock for up to every ten shares of Common Stock held ; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof. Duyuru • Oct 05
China Pharma Holdings Receives Notification from the NYSE American On September 27, 2023, China Pharma Holdings, Inc. received notification from the NYSE AMERICAN LLC informing it that the Company is not in compliance with certain NYSE American continued listing standards. The Deficiency Letter indicated that the Company’s securities had been selling for a low price per share for a substantial period of time and most recently the average price of the Company’s common stock had been below $0.20 on a 30-day average price. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company’s continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the staff determined to be no later than March 27, 2024. The Company remains subject to the conditions set in the NYSE American’s letter dated June 15, 2022 for stockholders’ equity noncompliance, as previously reported on the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022. The Company intends to regain compliance with the Listing Standards by undertaking a measure or measures that are for the best interests of the Company and its stockholders. The Company’s common stock will continue to be listed on the NYSE American while it attempts to regain compliance with the Listing Standards, subject to the Company’s compliance with other continued listing requirements. The NYSE American notification does not affect the Company’s business operations or its reporting obligations under the Securities and Exchange Commission regulations and rules and does not conflict with or cause an event of default under any of the Company’s material agreements. Reported Earnings • Aug 16
Second quarter 2023 earnings released: US$0.06 loss per share (vs US$0.18 loss in 2Q 2022) Second quarter 2023 results: US$0.06 loss per share (improved from US$0.18 loss in 2Q 2022). Revenue: US$1.10m (down 32% from 2Q 2022). Net loss: US$593.0k (loss narrowed 33% from 2Q 2022). Reported Earnings • May 14
First quarter 2023 earnings released: US$0.059 loss per share (vs US$0.22 loss in 1Q 2022) First quarter 2023 results: US$0.059 loss per share (improved from US$0.22 loss in 1Q 2022). Revenue: US$1.96m (up 22% from 1Q 2022). Net loss: US$476.0k (loss narrowed 54% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 02
Full year 2022 earnings released: US$0.76 loss per share (vs US$0.74 loss in FY 2021) Full year 2022 results: US$0.76 loss per share (further deteriorated from US$0.74 loss in FY 2021). Revenue: US$8.10m (down 16% from FY 2021). Net loss: US$3.97m (loss widened 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 17
Third quarter 2022 earnings released: US$0.016 loss per share (vs US$0.018 loss in 3Q 2021) Third quarter 2022 results: US$0.016 loss per share (improved from US$0.018 loss in 3Q 2021). Revenue: US$1.97m (flat on 3Q 2021). Net loss: US$790.8k (loss narrowed 4.3% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Director Heung Mei Tsui was the last director to join the board, commencing their role in 2009. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 16
Second quarter 2022 earnings released: US$0.018 loss per share (vs US$0.018 loss in 2Q 2021) Second quarter 2022 results: US$0.018 loss per share (vs US$0.018 loss in 2Q 2021). Revenue: US$1.61m (down 33% from 2Q 2021). Net loss: US$888.4k (loss widened 7.7% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.022 loss per share (down from US$0.017 loss in 1Q 2021). Revenue: US$1.60m (down 32% from 1Q 2021). Net loss: US$1.03m (loss widened 34% from 1Q 2021). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Director Heung Mei Tsui was the last director to join the board, commencing their role in 2009. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: US$0.074 loss per share (down from US$0.066 loss in FY 2020). Revenue: US$9.64m (down 11% from FY 2020). Net loss: US$3.40m (loss widened 19% from FY 2020). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 1Q 2020) The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.36m (up 34% from 1Q 2020). Net loss: US$767.3k (loss widened 16% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 28
Full year 2020 earnings released: US$0.066 loss per share (vs US$0.47 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were flat. Full year 2020 results: Revenue: US$10.9m (flat on FY 2019). Net loss: US$2.87m (loss narrowed 86% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 09
New 90-day high: US$0.93 The company is up 129% from its price of US$0.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Jan 22
New 90-day high: US$0.74 The company is up 60% from its price of US$0.46 on 23 October 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. Is New 90 Day High Low • Jan 06
New 90-day high: US$0.56 The company is up 49% from its price of US$0.37 on 07 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Nov 25
New 90-day high: US$0.55 The company is up 36% from its price of US$0.40 on 26 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: US$0.023 loss per share The company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$2.40m (up 1.0% from 3Q 2019). Net loss: US$1.01m (loss widened 44% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. 
